Evaluation of cost-effectiveness of peginterferon plus ribavirin for chronic hepatitis C treatment and direct-acting antiviral agents among HIV-infected patients in the prison and community settings

ConclusionsChronic HCV/HIV co-infected patients with genotype 1 and 6 in the community setting could benefit from DAAs in Taiwan. (Source: Journal of Microbiology, Immunology and Infection)

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2OleYCJ